Cargando…
Implementing oncology clinical trials in Nigeria: a model for capacity building
BACKGROUND: There is both higher mortality and morbidity from cancer in low and medium income countries (LMICs) compared with high income countries (HICs). Clinical trial activities and development of more effective and less toxic therapies have led to significant improvements in morbidity and morta...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397583/ https://www.ncbi.nlm.nih.gov/pubmed/32746811 http://dx.doi.org/10.1186/s12913-020-05561-3 |
_version_ | 1783565797634867200 |
---|---|
author | Ntekim, Atara Ibraheem, Abiola Adeniyi-Sofoluwe, Adenike Adepoju, Toyosi Oluwasanu, Mojisola Aniagwu, Toyin Awolude, Olutosin Balogun, Williams Kotila, Olayinka Adejumo, Prisca Babalola, Chinedum Peace Arinola, Ganiyu Ojengbede, Oladosu Olopade, Christopher O. Olopade, Olufunmilayo I. |
author_facet | Ntekim, Atara Ibraheem, Abiola Adeniyi-Sofoluwe, Adenike Adepoju, Toyosi Oluwasanu, Mojisola Aniagwu, Toyin Awolude, Olutosin Balogun, Williams Kotila, Olayinka Adejumo, Prisca Babalola, Chinedum Peace Arinola, Ganiyu Ojengbede, Oladosu Olopade, Christopher O. Olopade, Olufunmilayo I. |
author_sort | Ntekim, Atara |
collection | PubMed |
description | BACKGROUND: There is both higher mortality and morbidity from cancer in low and medium income countries (LMICs) compared with high income countries (HICs). Clinical trial activities and development of more effective and less toxic therapies have led to significant improvements in morbidity and mortality from cancer in HICs. Unfortunately, clinical trials remain low in LMICs due to poor infrastructure and paucity of experienced personnel to execute clinical trials. There is an urgent need to build local capacity for evidence-based treatment for cancer patients in LMICs. METHODS: We conducted a survey at facilities in four Teaching Hospitals in South West Nigeria using a checklist of information on various aspects of clinical trial activities. The gaps identified were addressed using resources sourced in partnership with investigators at HIC institutions. RESULTS: Deficits in infrastructure were in areas of patient care such as availability of oncology pharmacists, standard laboratories and diagnostic facilities, clinical equipment maintenance and regular calibrations, trained personnel for clinical trial activities, investigational products handling and disposals and lack of standard operating procedures for clinical activities. There were two GCP trained personnel, two study coordinators and one research pharmacist across the four sites. Interventions were instituted to address the observed deficits in all four sites which are now well positioned to undertake clinical trials in oncology. Training on all aspects of clinical trial was also provided. CONCLUSIONS: Partnerships with institutions in HICs can successfully identify, address, and improve deficits in infrastructure for clinical trial in LMICs. The HICs should lead in providing funds, mentorship, and training for LMIC institutions to improve and expand clinical trials in LMIC countries. |
format | Online Article Text |
id | pubmed-7397583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73975832020-08-06 Implementing oncology clinical trials in Nigeria: a model for capacity building Ntekim, Atara Ibraheem, Abiola Adeniyi-Sofoluwe, Adenike Adepoju, Toyosi Oluwasanu, Mojisola Aniagwu, Toyin Awolude, Olutosin Balogun, Williams Kotila, Olayinka Adejumo, Prisca Babalola, Chinedum Peace Arinola, Ganiyu Ojengbede, Oladosu Olopade, Christopher O. Olopade, Olufunmilayo I. BMC Health Serv Res Research Article BACKGROUND: There is both higher mortality and morbidity from cancer in low and medium income countries (LMICs) compared with high income countries (HICs). Clinical trial activities and development of more effective and less toxic therapies have led to significant improvements in morbidity and mortality from cancer in HICs. Unfortunately, clinical trials remain low in LMICs due to poor infrastructure and paucity of experienced personnel to execute clinical trials. There is an urgent need to build local capacity for evidence-based treatment for cancer patients in LMICs. METHODS: We conducted a survey at facilities in four Teaching Hospitals in South West Nigeria using a checklist of information on various aspects of clinical trial activities. The gaps identified were addressed using resources sourced in partnership with investigators at HIC institutions. RESULTS: Deficits in infrastructure were in areas of patient care such as availability of oncology pharmacists, standard laboratories and diagnostic facilities, clinical equipment maintenance and regular calibrations, trained personnel for clinical trial activities, investigational products handling and disposals and lack of standard operating procedures for clinical activities. There were two GCP trained personnel, two study coordinators and one research pharmacist across the four sites. Interventions were instituted to address the observed deficits in all four sites which are now well positioned to undertake clinical trials in oncology. Training on all aspects of clinical trial was also provided. CONCLUSIONS: Partnerships with institutions in HICs can successfully identify, address, and improve deficits in infrastructure for clinical trial in LMICs. The HICs should lead in providing funds, mentorship, and training for LMIC institutions to improve and expand clinical trials in LMIC countries. BioMed Central 2020-08-03 /pmc/articles/PMC7397583/ /pubmed/32746811 http://dx.doi.org/10.1186/s12913-020-05561-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Ntekim, Atara Ibraheem, Abiola Adeniyi-Sofoluwe, Adenike Adepoju, Toyosi Oluwasanu, Mojisola Aniagwu, Toyin Awolude, Olutosin Balogun, Williams Kotila, Olayinka Adejumo, Prisca Babalola, Chinedum Peace Arinola, Ganiyu Ojengbede, Oladosu Olopade, Christopher O. Olopade, Olufunmilayo I. Implementing oncology clinical trials in Nigeria: a model for capacity building |
title | Implementing oncology clinical trials in Nigeria: a model for capacity building |
title_full | Implementing oncology clinical trials in Nigeria: a model for capacity building |
title_fullStr | Implementing oncology clinical trials in Nigeria: a model for capacity building |
title_full_unstemmed | Implementing oncology clinical trials in Nigeria: a model for capacity building |
title_short | Implementing oncology clinical trials in Nigeria: a model for capacity building |
title_sort | implementing oncology clinical trials in nigeria: a model for capacity building |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397583/ https://www.ncbi.nlm.nih.gov/pubmed/32746811 http://dx.doi.org/10.1186/s12913-020-05561-3 |
work_keys_str_mv | AT ntekimatara implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT ibraheemabiola implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT adeniyisofoluweadenike implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT adepojutoyosi implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT oluwasanumojisola implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT aniagwutoyin implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT awoludeolutosin implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT balogunwilliams implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT kotilaolayinka implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT adejumoprisca implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT babalolachinedumpeace implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT arinolaganiyu implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT ojengbedeoladosu implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT olopadechristophero implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding AT olopadeolufunmilayoi implementingoncologyclinicaltrialsinnigeriaamodelforcapacitybuilding |